Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2007
Issue release date: February 2007
Dement Geriatr Cogn Disord 2007;23:161–167

Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson’s Disease with Dementia and Dementia with Lewy Bodies

Rowan E. · McKeith I.G. · Saxby B.K. · O’Brien J.T. · Burn D. · Mosimann U. · Newby J. · Daniel S. · Sanders J. · Wesnes K.
aInstitute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, bCognitive Drug Research Ltd., CDR House, Goring-on-Thames, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) by means of open label study. Methods: 22 DLBs and 23 PDDs were assessed over 20 weeks using the Cognitive Drug Research Computerized Attentional Tasks. We examined how much closer our patients moved towards being normal for their age by comparing them to a non-demented elderly control sample (n = 183, aged 71–75 years). Results: Donepezil treatment improved power of attention, continuity of attention and reaction time variability. The deficit in responses was moved towards normal by 38 and 56% for power of attention and 22 and 10% for continuity of attention in PDD and DLB, respectively. Conclusions: Improvements in attention were found with donepezil in PDD and DLB.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Poirier J: Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127:6–19.
  2. Ballard CG, Aarsland D, McKeith I, O’Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M: Fluctuations in attention: PD dementia vs. DLB with parkinsonism. Neurology 2002;59:1714–1720.
  3. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD: Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 2003;108:368–373.
  4. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–2518.
  5. Thomas A, Burn D, Rowan E, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith I: A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938–944.
  6. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, Littlewood E, Myint P, Newby J, McKeith IG: What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003;18:988–993.
  7. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R: Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183– 192.
  8. McKeith IG, Wesnes KA, Perry E, Ferrara R: Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94–100.
  9. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654–1656.
  10. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113– 1124.
  11. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.
  12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
  13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  14. Fahn S, Elton RL: Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Goldstein M, Calne DB (eds): Recent Developments in Parkinson’s Disease. Florham Park, MacMillan, 1987, vol 2, pp 153–163.
  15. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B: Validity and reliability of the Alzheimer’s Disease Cooperative Society – Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11:22–32.
  16. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K: Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113–120.
  17. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, Ballard CG: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. BrJ Psychiatry 2000;177:252–256.
  18. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK: The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95–102.

    External Resources

  19. Tasker A, Perry EK, Ballard CG: Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev Neurother 2005;5:101–106.
  20. Vellas B, Cunha L, Gertz H-J, De Deyn P, Wesnes K, Hammond G, Schwalen S: Early onset effects of galantamine treatment on attention in patients with Alzheimer’s disease. Curr Med Res Opin 2005;21:1423–1429.
  21. Touchon J, Bergman H, Bullock R, Raptz G, Nagel J, Lane R: Response to rivastigmine or donepezil in Alzheimer’s patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin2006;22:49–59.
  22. Bhasin M, Rowan E, Edwards K, McKeith I: Cholinesterase inhibitors in Dementia with Lewy Bodies – A comparative analysis. Int J Geriatr Psychiatry (in press).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50